Case Study

Randomizing 1,500+ Participants for a Phase 3 Flu Vaccine Program

Across seven sites in three states, Tekton centralized startup and recruitment for a Phase 3 influenza vaccine research program. All seven sites exceeded their goals, more than 340 participants were randomized at Tekton’s Austin site, and Tekton randomized more than 1,500 participants across the overall research program.

  • All seven Tekton sites exceeded their goals
  • Delivered 169% of the combined initial enrollment goal
  • More than 1,500 participants randomized by Tekton across the research program
  • More than 340 participants randomized at Tekton’s Austin site
  • Research culminated in product approval

Talk to Tekton

COVID-19 Vaccine Research Study

About This Study

CLIENT
Leading global vaccine developer
TRIAL
Phase 3 influenza vaccine research program
TEKTON COVERAGE
Seven sites
PROGRAM OUTCOME
Product approved

Partner With Tekton

Join leading Sponsors and CROs that trust Tekton's sites to support their most important clinical trials.

Complete the form on this page or email to discuss your protocol, target population, timelines, and site needs.

Submit Your Information